Literature DB >> 18000399

Phosphorylated LIM kinases colocalize with gamma-tubulin in centrosomes during early stages of mitosis.

Ratna Chakrabarti1, Jennifer L Jones, Denise K Oelschlager, Tenekua Tapia, Albert Tousson, William E Grizzle.   

Abstract

LIM kinases (LIMK1 and LIMK2) are LIM domain containing serine/threonine kinases that modulate reorganization of actin cytoskeleton through inactivating phosphorylation of cofilin. The Rho family of small GTPases regulates the catalytic activity of LIMK1 and LIMK2 through activating phosphorylation by ROCK or by p21 kinase. Recent studies have suggested that LIMK1 could play a role in modulation of cellular growth by alteration of the cell cycle in breast and prostate tumor cells; however, the direct mitogenic effects of LIMK1 in these tumor cells is yet to be elucidated. Via immunofluorescence, in this study, we show that phosphorylated LIM kinases (pLIMK1/2) are colocalized with gamma-tubulin in the centrosomes during the early mitotic phases of human breast and prostate cancer cells (MDA-MB-231 and DU145); apparent colocalization begins in the centrosomes in prophase. As shown by both bright field (MDA-MB-231) and fluorescent immunohistochemistry (MDA-MB-231 and DU145), pLIMK1/2 does not localize to centrosomes during interphase. By bright field immunohistochemistry, the largest area of the centrosome that is stained with pLIMK1/2 occurs at anaphase. In early telophase, reduced staining of pLIMK1/2 at the spindle poles and concomitant accumulation of pLIMK1/2 at the cleavage furrow begins to occur. In late telophase, loss of staining of pLIMK1/2 and of colocalization with gamma-tubulin occurs at the poles and pLIMK1/2 became further concentrated at the junction between the two daughter cells. Co-immunoprecipitation studies indicated that gamma-tubulin associates with phosphorylated LIMK1 and LIMK2 but not with dephosphorylated LIMK1 or LIMK2. The results suggest that activated LIMK1/2 may associate with gamma-tubulin and play a role in mitotic spindle assembly.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18000399     DOI: 10.4161/cc.6.23.4957

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  10 in total

1.  Phosphorylation of CHO1 by Lats1/2 regulates the centrosomal activation of LIMK1 during cytokinesis.

Authors:  Ayumi Okamoto; Norikazu Yabuta; Satomi Mukai; Kosuke Torigata; Hiroshi Nojima
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Aberrant expression of LMO4 induces centrosome amplification and mitotic spindle abnormalities in breast cancer cells.

Authors:  Marjorie E Montañez-Wiscovich; Melissa D Shelton; Darcie D Seachrist; Kristen L Lozada; Emhonta Johnson; John D Miedler; Fadi W Abdul-Karim; Jane E Visvader; Ruth A Keri
Journal:  J Pathol       Date:  2010-11       Impact factor: 7.996

Review 3.  Aurora A kinase (AURKA) in normal and pathological cell division.

Authors:  Anna S Nikonova; Igor Astsaturov; Ilya G Serebriiskii; Roland L Dunbrack; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2012-08-03       Impact factor: 9.261

4.  A functional cooperativity between Aurora A kinase and LIM kinase1: implication in the mitotic process.

Authors:  Lisa Ritchey; Richard Ottman; Michael Roumanos; Ratna Chakrabarti
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

5.  LIM kinase 1 - dependent cofilin 1 pathway and actin dynamics mediate nuclear retinoid receptor function in T lymphocytes.

Authors:  Mohammad Ishaq; Bor-Ruei Lin; Marjorie Bosche; Xin Zheng; Jun Yang; Dawei Huang; Richard A Lempicki; Angelica Aguilera-Gutierrez; Ven Natarajan
Journal:  BMC Mol Biol       Date:  2011-09-16       Impact factor: 2.946

6.  YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification.

Authors:  A H Davies; I Barrett; M R Pambid; K Hu; A L Stratford; S Freeman; I M Berquin; S Pelech; P Hieter; C Maxwell; S E Dunn
Journal:  Oncogene       Date:  2011-03-21       Impact factor: 9.867

Review 7.  LIM kinases: cofilin and beyond.

Authors:  Chloé Prunier; Renaud Prudent; Reuben Kapur; Karin Sadoul; Laurence Lafanechère
Journal:  Oncotarget       Date:  2017-06-20

8.  LIM kinase1 regulates mitotic centrosome integrity via its activity on dynein light intermediate chains.

Authors:  Sirong Ou; Mei-Hua Tan; Ting Weng; HoiYeung Li; Cheng-Gee Koh
Journal:  Open Biol       Date:  2018-06       Impact factor: 6.411

9.  LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation.

Authors:  Katerina Mardilovich; Mark Baugh; Diane Crighton; Dominika Kowalczyk; Mads Gabrielsen; June Munro; Daniel R Croft; Filipe Lourenco; Daniel James; Gabriella Kalna; Lynn McGarry; Oliver Rath; Emma Shanks; Mathew J Garnett; Ultan McDermott; Joanna Brookfield; Mark Charles; Tim Hammonds; Michael F Olson
Journal:  Oncotarget       Date:  2015-11-17

10.  Nonconserved miR-608 suppresses prostate cancer progression through RAC2/PAK4/LIMK1 and BCL2L1/caspase-3 pathways by targeting the 3'-UTRs of RAC2/BCL2L1 and the coding region of PAK4.

Authors:  Xu Zhang; Jiajie Fang; Shiming Chen; Weiyu Wang; Shuai Meng; Ben Liu
Journal:  Cancer Med       Date:  2019-08-07       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.